Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011)
Nektar Therapeutics (NKTR) posted quarterly Convertible Debt of $215.0 million for Q4 2011, little changed year-over-year from $215.0 million in Q4 2010, and little changed quarter-over-quarter from $215.0 million in Q2 2011.
Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011) Analysis & Trends
Nektar Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $215.0 million for Q4 2011.
- In Q4 2011, Convertible Debt changed 0.0% year-over-year to $215.0 million; the TTM figure through Dec 2011 stood at $215.0 million (changed 0.0% YoY), while the FY2011 annual figure was $215.0 million, changed 0.0% from the prior year.
- Convertible Debt for Q4 2011 stood at $215.0 million, roughly flat from $215.0 million in the prior quarter.
- The five-year high for Convertible Debt was $215.0 million in Q4 2010, with the low at $215.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 214.96 Mn |
| Jun 30, 2011 | 214.96 Mn |
| Mar 31, 2011 | 214.96 Mn |
| Dec 31, 2010 | 214.96 Mn |